05/25/22 7:00 AMOTC, Nasdaq : ATBPF, ASLN managementAntibe Therapeutics Appoints New Board Chair and Corporate Vice ChairsAntibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. Dr. Wallace is also taking the opportunity to return to his vocation as a...RHEA-AIneutral
05/20/22 7:00 AMNasdaq : ASLN ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual MeetingASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlightingRHEA-AIneutral
05/18/22 7:00 AMNasdaq : ASLN conferencesASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present aRHEA-AIneutral
05/10/22 7:00 AMNasdaq : ASLN ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual MeetingASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting new data andRHEA-AIneutral
04/27/22 7:00 AMNasdaq : ASLN earningsASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023 Alex Kaoukhov, MD, appointed as Chief Medical Officer, adding global pharma leadership experience ahead of advancing eblasakimabRHEA-AIneutral
04/12/22 8:00 AMNasdaq : ASLN managementOak Hill Bio Announces Formation of Board of DirectorsOak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced the formation of the Company’ s Board of Directors, which brings together a team of experienced leaders with collective expertise...RHEA-AIneutral
04/06/22 7:00 AMNasdaq : ASLN conferencesASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present atRHEA-AIneutral
04/01/22 5:00 PMNasdaq : ASLN ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLCRHEA-AIneutral
03/28/22 7:00 AMNasdaq : ASLN ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual MeetingASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from theRHEA-AIneutral
03/25/22 7:00 AMNasdaq : ASLN earningsASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023 New CMO appointed, adding senior global pharma experience to the leadership team Company maintains strong operating position with US$90.2 million in cashRHEA-AIneutral